Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jayde Wall

Nurse Practitioner, Gerontology Indianapolis, IN Nurse Practitioner

NPI 1013566884 CMS profile 11162056

1030 W Michigan St Fl 2, Indianapolis, IN 46202

Open in the dashboard

General payments

$2,117

50 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jayde Wall of Indianapolis, IN is reported in the CMS Open Payments database as having received $2,117 across 50 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $198 6
2024 General $521 16
2023 General $574 11
2022 General $481 12
2021 General $343 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jayde Wall
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Jayde Wall were reported at $198. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Jayde Wall Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $343 $133 $44–$396 $132
2022 $481 $142 $48–$452 $149
2023 $574 $158 $53–$482 $160
2024 $521 $171 $55–$533 $164
2025 $198 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $457 9 payments
  2. Eisai Inc. $404 13 payments
  3. Merck Sharp & Dohme Corporation $348 16 payments
  4. AstraZeneca Pharmaceuticals LP $330 4 payments
  5. ImmunoGen, Inc. $241 2 payments
  6. AbbVie, Inc. $128 2 payments
  7. Seattle Genetics, Inc. $100 1 payment
  8. Clovis Oncology, Inc. $85 2 payments
  9. Novartis Pharmaceuticals Corporation $25 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,942 48 payments
  2. Education $175 2 payments
Products named General payments · program years 2021–2025
  1. Lenvima $404 13 payments
  2. LYNPARZA Oncology $330 4 payments
  3. ZEJULA $271 7 payments
  4. KEYTRUDA $258 11 payments
  5. Elahere Oncology $241 2 payments
  6. LYNPARZA Oncology $187 11 payments
  7. ELAHERE Oncology $128 2 payments
  8. TAFINLAR $25 1 payment
  9. MEKINIST $25 1 payment
  10. Rubraca $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

291

Median for Nurse Practitioner: 389

Drug cost

$328,846

Median for Nurse Practitioner: $21,885

Branded share of claims

20.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lynparza Olaparib Brand 18 $313,643
Eliquis Apixaban Brand 13 $9,010
Megestrol Acetate Generic 23 $1,277
Lidocaine Generic 12 $952
Medroxyprogesterone Acetate Generic 19 $764
Ondansetron Hcl Generic 31 $657
Potassium Chloride Generic 17 $574
Dexamethasone Sodium Phosphate Generic 14 $508
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 18 $309
Triamcinolone Acetonide Generic 12 $306

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$12,634

Medicare's payments for the services billed

Medicare patients

121

Average age 72

Services billed

288

121 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Cancer 69%
Arthritis 40%
Chronic kidney disease 29%
Depression 29%
Diabetes 27%
Atrial fibrillation 17%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Lenvima
  • Eisai Inc. $169
$169 — —
ELAHERE
  • AbbVie, Inc. $128
$128 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $35
  • AstraZeneca Pharmaceuticals LP $23
$58 18 —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $46
$46 — —
ZEJULA
  • GlaxoSmithKline, LLC. $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record